RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2015
At a glance
- Drugs RI 002 (Primary)
- Indications Immunological disorders; Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors ADMA Biologics
- 21 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Feb 2010 Planned end date changed from 1 May 2009 to 1 May 2010 as reported by ClinicalTrials.gov.
- 10 Jul 2008 New trial record.